Mibefradil - A drug which may enhance the propensity for the development of abnormal QT prolongation

European Heart Journal, Supplement

Volumn 3, Issue K, 2001, Pages

  Meinertz, Thomas ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cardiac repolarization; Drug interactions; Mibefradil

Indexed keywords

AMIODARONE; ASTEMIZOLE; BEPRIDIL; CALCIUM ANTAGONIST; CALCIUM CHANNEL T TYPE; CISAPRIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DESIPRAMINE; ERYTHROMYCIN; ETOPOSIDE; FLECAINIDE; FLUTAMIDE; HALOFANTRINE; IFOSFAMIDE; IMIPRAMINE; MEVINOLIN; MEXILETINE; MIBEFRADIL; PIMOZIDE; QUINIDINE; SIMVASTATIN; SOTALOL; TACROLIMUS; TAMOXIFEN; TERFENADINE; THIORIDAZINE; VINBLASTINE; VINCRISTINE;

ANGINA PECTORIS; CONFERENCE PAPER; DRUG MARKETING; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; HEART REPOLARIZATION; HUMAN; HYPERTENSION; LONG QT SYNDROME; PRIORITY JOURNAL;

EID: 0034811735     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(01)90011-2     Document Type: Conference Paper

References (7)

1. Protecting patients from harm: Terfenadine and potential drug therapy interactions
2. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967). A new generation of calcium antagonist?
3. 2+ channels by Ro 40-5967
4. Effect of mibefradil, a T-type calcium channel blocker on morbidity and mortality in moderate to severe congestive heart failure. The MACH-1 Study
5. Withdrawal of posicor from market
6. What lessons can be learnt from withdrawal of mibefradil from the market?